|Values are valid only on day of printing.|
Lipoprotein(a) (Lp[a]) is a highly heterogeneous molecule, consisting of a low-density lipoprotein (LDL) with a highly glycosylated apolipoprotein(a) (apo[a]) covalently linked to the apolipoprotein B moiety of LDL via a single disulfate bond. Lp(a) has been associated with atherogenesis and promotion of thrombosis. Increased levels of Lp(a) have been estimated to confer a 1.5 to 3.0-fold increased risk for coronary artery disease (CAD) in many but not all studies. Apo(a) has approximately 80% structural homology with plasminogen, but does not contain the active site for fibrin cleavage. One proposed mechanism for Lp(a)'s atherogenicity is competition for binding sites with plasminogen during fibrin clot formation and the resulting inhibition of fibrinolysis. Recently a high correlation was demonstrated between Lp(a) and oxidized LDL, suggesting that the atherogenicity of Lp(a) lipoprotein may be mediated in part by associated proinflammatory oxidized phospholipids.
The heterogeneity of Lp(a) arises mainly from the variable number of kringle repeats in the apo(a) portion of the molecule. Kringles are specific structural domains containing 3 intra-strand disulfide bonds that are highly homologous to similar repeats found in plasminogen.
In the clinical laboratory, immunologic methods are generally used to quantify Lp(a) protein mass. Reagents for Lp(a) mass measurement are available from multiple manufacturers and although standardization efforts are underway, currently available methods are not standardized. Difficulties in standardizing Lp(a) mass measurement arise from the variability in signals produced by different reagents due to the size polymorphisms of apo(a). For this reason, some elevations of Lp(a) mass are associated with low levels of Lp(a) cholesterol. Lp(a) quantification can be done by densitometric measurement of Lp(a) cholesterol. This method measures only the cholesterol contained in the Lp(a) particles and is thus not influenced by the relative size of the apo(a) particle. Because Lp(a) cholesterol measurement is not influenced by apo(a) size, it may provide a more specific assessment of cardiovascular risk than Lp(a) mass measurement. Lp(a) cholesterol measurement may be used in concert with Lp(a) mass determination, or may be used as a stand-alone test for assessment of risk.
Evaluation of increased risk for cardiovascular disease and events:
-Most appropriately measured in individuals at intermediate risk for cardiovascular disease
-Patients with early atherosclerosis or strong family history of early atherosclerosis without explanation by traditional risk factors should also be considered for testing
Follow-up evaluation of patients with measurable lipoprotein(a) protein (LIPA)
Patients with increased Lp(a) cholesterol values have an approximate 2-fold increased risk for developing cardiovascular disease and events.
Lipoprotein-X (LpX) is an abnormal lipoprotein that appears in the sera of patients with obstructive jaundice, and is an indicator of cholestasis. The presence of LpX will be reported if noted during Lp(a) cholesterol analysis.
Lp(a) cholesterol values should not be confused with Lp(a) mass values, although they may be correlated in some individual cases. Lp(a) cholesterol values will be approximately 10 times lower than Lp(a) mass values, but the difference between the measures is not uniform. Lp(a) mass values are considered elevated when >30 mg/dL. Lp(a) cholesterol is increased if > or =3 mg/dL.
Normal: <3 mg/dL
Suggests increased risk of coronary artery disease: > or =3 mg/dL
1. Berg K: Lp(a) lipoprotein: an overview. Chem Phys Lipids 1994;67-68:9-16
2. Rhoads GG, Dahlen G, Berg K et al: Lp(a) lipoproteins as a risk factor for myocardial infarction. JAMA 1986;256:2540-2544
3. Bostom AG, Cupples LA, Jenner JL, et al: Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996;276:544-548
4. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-2199
5. Tsimikas S, Brilakis ES, Miller ER, et al: Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353(1):46-57
6. Baudhuin LM, Hartman SJ, O'Brien JF, et al: Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: comparison with an immunoturbidimetric lipoprotein[a] method. Clin Biochem 2004 June;37:481-488
7. McConnell JP, Baudhuin LM, Berger PB, et al: Lipoprotein (a) cholesterol, but not Lp(a) mass, is an independent predictor of angiographic coronary artery disease and subsequent cardiovascular events in patients referred for coronary angiography. Circulation 2007;116:II_818